Dexamethasoni phosphas

Administration of topical steroids is not recommended in cases of ocular redness of unknown cause. Patients should be monitored at frequent intervals during treatment with dexamethasone eye drops. Prolonged use of corticosteroids may lead to ocular hypertension/glaucoma (particularly in patients with previous steroid-induced IOP elevation or with pre-existing raised IOP or glaucoma) and to cataract formation, especially in children and elderly patients. Use of corticosteroids may also result in opportunistic ocular infections due to suppression of the host response or delayed healing. In addition, topical ocular corticosteroids may promote, exacerbate or mask the signs and symptoms of opportunistic ocular infections. Patients with an ocular infection should receive topical steroid therapy only if the infection has been controlled with effective anti-infective treatment. These patients must be carefully and regularly monitored by an ophthalmologist. In certain specific inflammatory conditions, such as episcleritis, NSAIDs are the first-line treatment; dexamethasone should be used only when NSAIDs are contraindicated. Patients with corneal ulcer should generally not receive topical dexamethasone, except in cases where inflammation is the primary cause of delayed healing and appropriate causal therapy has already been prescribed. These patients must be carefully and regularly monitored by an ophthalmologist. Corneal and scleral thinning may increase the risk of perforation with the use of topical corticosteroids. Posterior subcapsular cataract may occur with cumulative doses of dexamethasone. Patients with diabetes mellitus are also more susceptible to developing subcapsular cataracts following topical steroid administration. The use of topical steroids in allergic conjunctivitis is recommended only in severe forms unresponsive to standard therapy, and only for a short period. Cushing's syndrome and/or adrenal suppression associated with systemic absorption of ocular dexamethasone may occur after intensive or prolonged continuous treatment in predisposed patients, including children and patients treated with CYP3A4 inhibitors (including ritonavir and cobicistat). In such cases, treatment should be gradually withdrawn. Patients with a history of contact hypersensitivity to silver should not use this product, as the administered drops may contain trace amounts of silver. Visual disturbances Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which has been reported after use of systemic and topical corticosteroids. The wearing of contact lenses should be avoided during treatment with corticosteroid eye drops.